BR112016005000A8 - combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, composto - Google Patents
combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, compostoInfo
- Publication number
- BR112016005000A8 BR112016005000A8 BR112016005000A BR112016005000A BR112016005000A8 BR 112016005000 A8 BR112016005000 A8 BR 112016005000A8 BR 112016005000 A BR112016005000 A BR 112016005000A BR 112016005000 A BR112016005000 A BR 112016005000A BR 112016005000 A8 BR112016005000 A8 BR 112016005000A8
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- methyl
- compound
- pharmaceutical composition
- kit
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- NAGFMACWWJYORB-UHFFFAOYSA-N 2-fluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1F NAGFMACWWJYORB-UHFFFAOYSA-N 0.000 abstract 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 abstract 1
- -1 3- (4-cyano-3- (trifluoromethyl) phenyl) -5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940125520 PI3Kβ inhibitor Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361879895P | 2013-09-19 | 2013-09-19 | |
| PCT/US2014/055816 WO2015042029A1 (en) | 2013-09-19 | 2014-09-16 | Combination drug therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016005000A8 true BR112016005000A8 (pt) | 2018-01-23 |
Family
ID=52689320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016005000A BR112016005000A8 (pt) | 2013-09-19 | 2014-09-16 | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, composto |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160228446A1 (https=) |
| EP (1) | EP3046556A4 (https=) |
| JP (3) | JP6346944B2 (https=) |
| KR (1) | KR20160055911A (https=) |
| CN (1) | CN105530934A (https=) |
| AU (1) | AU2014321456B2 (https=) |
| BR (1) | BR112016005000A8 (https=) |
| CA (1) | CA2921156A1 (https=) |
| RU (1) | RU2016110546A (https=) |
| WO (1) | WO2015042029A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014321456B2 (en) * | 2013-09-19 | 2018-05-24 | Glaxosmithkline Llc | Combination drug therapy |
| US10206949B2 (en) | 2015-09-21 | 2019-02-19 | Ofer Agam | Composition that relieves heartburn, GERD and hangovers |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US20210393651A1 (en) * | 2018-11-09 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4644737B2 (ja) * | 2005-05-13 | 2011-03-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールヒダントイン化合物 |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP5198289B2 (ja) * | 2006-02-03 | 2013-05-15 | イムクローン・リミテッド・ライアビリティ・カンパニー | 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト |
| LT2656842T (lt) * | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| PL2538785T3 (pl) * | 2010-02-24 | 2018-08-31 | Medivation Prostate Therapeutics Llc | Sposoby syntezy zwiazków diarylotiohydantoinowych i diarylohydantoinowych |
| JP5719028B2 (ja) * | 2010-10-06 | 2015-05-13 | グラクソスミスクライン エルエルシー | Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体 |
| DK2683694T3 (en) * | 2011-03-10 | 2016-07-18 | Suzhou Kintor Pharmaceuticals Inc | ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| EP2943199A1 (en) * | 2013-01-09 | 2015-11-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Combination |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| AU2014321456B2 (en) * | 2013-09-19 | 2018-05-24 | Glaxosmithkline Llc | Combination drug therapy |
-
2014
- 2014-09-16 AU AU2014321456A patent/AU2014321456B2/en not_active Ceased
- 2014-09-16 CA CA2921156A patent/CA2921156A1/en not_active Abandoned
- 2014-09-16 RU RU2016110546A patent/RU2016110546A/ru not_active Application Discontinuation
- 2014-09-16 EP EP14846138.7A patent/EP3046556A4/en not_active Withdrawn
- 2014-09-16 KR KR1020167009965A patent/KR20160055911A/ko not_active Ceased
- 2014-09-16 BR BR112016005000A patent/BR112016005000A8/pt not_active IP Right Cessation
- 2014-09-16 CN CN201480051583.9A patent/CN105530934A/zh active Pending
- 2014-09-16 JP JP2016515414A patent/JP6346944B2/ja not_active Expired - Fee Related
- 2014-09-16 WO PCT/US2014/055816 patent/WO2015042029A1/en not_active Ceased
- 2014-09-16 US US15/022,561 patent/US20160228446A1/en not_active Abandoned
-
2018
- 2018-05-28 JP JP2018101120A patent/JP6563558B2/ja not_active Expired - Fee Related
-
2019
- 2019-07-24 JP JP2019135772A patent/JP2019196391A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6346944B2 (ja) | 2018-06-20 |
| RU2016110546A (ru) | 2017-10-24 |
| EP3046556A1 (en) | 2016-07-27 |
| CA2921156A1 (en) | 2015-03-26 |
| KR20160055911A (ko) | 2016-05-18 |
| AU2014321456B2 (en) | 2018-05-24 |
| JP2016530208A (ja) | 2016-09-29 |
| JP2018158930A (ja) | 2018-10-11 |
| US20160228446A1 (en) | 2016-08-11 |
| WO2015042029A1 (en) | 2015-03-26 |
| JP6563558B2 (ja) | 2019-08-21 |
| JP2019196391A (ja) | 2019-11-14 |
| CN105530934A (zh) | 2016-04-27 |
| RU2016110546A3 (https=) | 2018-03-20 |
| EP3046556A4 (en) | 2017-04-26 |
| AU2014321456A1 (en) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| JOP20190142B1 (ar) | مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر | |
| GEP20237506B (en) | Pcsk9 antagonist compounds | |
| BR112017017135A2 (pt) | inibidores de tgf-beta | |
| BR112015022483A2 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| GT201500088A (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015023412A2 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante | |
| ECSP11011412A (es) | Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso | |
| EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
| BRPI1015367B8 (pt) | derivados imidazo[2,1-b][1,3,4]tiadiazol | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
| BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |